Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers

NCT07736976 | Not Yet Recruiting

• 1 other identifier: E-78097791-020-5767
• Study Type: observational
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

Hemophilia is an inherited bleeding disorder characterized by recurrent musculoskeletal bleeding, particularly into joints, leading to impaired physical function and reduced functional performance. The 30-Second Sit-to-Stand Test (30STS) is a simple, reliable, and valid measure of lower extremity functional performance; however, evidence regarding its performance in individuals with hemophilia remains limited. This cross-sectional observational study aims to compare 30STS performance between adults with hemophilia and age-matched healthy controls and to investigate the relationship between 30STS performance, joint health, and activity level in individuals with hemophilia. Fifty-eight participants (29 individuals with hemophilia and 29 healthy controls) aged 18-35 years will be recruited. Participants will complete the 30STS. Individuals with hemophilia will additionally undergo joint health assessment using the Hemophilia Joint Health Score (HJHS) and activity evaluation using the Hemophilia Activities List (HAL).

Conditions

Hemophilia A and B

Keywords

hemophilia A; hemophilia B; 30-Second Sit-to-Stand Test; Functional Performance; Hemophilic Arthropathy

Outcome Measures

Primary Outcomes (1)

• 30-Second Sit-to-Stand Test Performance

  The primary outcome of this study is the performance on the 30-Second Sit-to-Stand Test (30STS). The test evaluates lower extremity functional performance by recording the number of correctly completed sit-to-stand repetitions within 30 seconds. The test will be performed once under standardized conditions in both the hemophilia group and healthy control group. Number of complete sit-to-stand repetitions performed from a standard chair within 30 seconds. Scores range from 0 to no fixed maximum, with higher scores indicating better lower extremity functional performance and muscle endurance.

  Baseline assessment (single assessment visit)

Secondary Outcomes (2)

• Joint Health Status Assessed by Hemophilia Joint Health Score (HJHS)

  Baseline assessment (single assessment visit)

• Hemophilia Activities List (HAL)

  Baseline assessment (single assessment visit)

Study Arms (2)

Hemophilia Group

Participants aged 18-35 years with a diagnosis of hemophilia A or hemophilia B.

Healthy Control Group

Age-matched healthy participants without hemophilia or other bleeding disorders.

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

This study will include adult males aged 18-35 years with a diagnosis of hemophilia A or hemophilia B and age-matched healthy male controls. Participants with hemophilia will be recruited from the members of the Turkish Hemophilia Society. Healthy controls without hemophilia or other bleeding disorders will be recruited from the general population. A total of 58 participants, including 29 individuals with hemophilia and 29 healthy controls, are planned to be included in the study.

You may qualify if:

• Hemophilia Group:
• Diagnosis of hemophilia A or hemophilia B
• Age between 18 and 35 years
• Ability to walk independently
• Willingness to participate in the study voluntarily
• Healthy Control Group:
• Age between 18 and 35 years
• No history of hemophilia or other bleeding disorders
• No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
• No neurological, rheumatological, or severe orthopedic disorders
• Willingness to participate in the study voluntarily

You may not qualify if:

• Hemophilia Group:
• \- Acute joint bleeding episode within the previous 3 months

Sponsors & Collaborators

• Bahçeşehir University: lead

Study Sites (1)

Bahcesehir university

Istanbul, Istanbul, 34353, Turkey (Türkiye)

Location

Related Publications (7)

• van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, de Kleijn P, van den Berg HM, Helders PJ. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia. 2004 Sep;10(5):565-71. doi: 10.1111/j.1365-2516.2004.01016.x.

  PMID: 15357785 BACKGROUND

• Kuijlaars IAR, van der Net J, Feldman BM, Aspdahl M, Bladen M, de Boer W, Cuesta-Barriuso R, Matlary RED, Funk SM, Hilliard P, John JA, Kempton CL, de Kleijn P, Manco-Johnson M, Petrini P, Poonnoose P, St-Louis J, Thomas S, Timmer MA, Trakymiene SS, van Vlimmeren L, Fischer K. Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia. 2020 Nov;26(6):1072-1080. doi: 10.1111/hae.14180. Epub 2020 Oct 15.

  PMID: 33058441 BACKGROUND

• McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J; 1000 Norms Project Consortium. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017 Apr 18;88(16):1512-1519. doi: 10.1212/WNL.0000000000003847. Epub 2017 Mar 22.

  PMID: 28330961 BACKGROUND

• Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020 Mar;105(3):545-553. doi: 10.3324/haematol.2019.232132. Epub 2020 Feb 14.

  PMID: 32060150 BACKGROUND

• Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012 May;18(3):e91-4. doi: 10.1111/j.1365-2516.2011.02588.x. Epub 2011 Jun 7.

  PMID: 21649801 BACKGROUND

• Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost. 2003 Jul;1(7):1349-55. doi: 10.1046/j.1538-7836.2003.00262.x.

  PMID: 12871268 BACKGROUND

• Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia. 2012 Jul;18 Suppl 4:148-53. doi: 10.1111/j.1365-2516.2012.02841.x.

  PMID: 22726099 BACKGROUND

MeSH Terms

Conditions

Hemophilia A; Hemophilia B

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, X-Linked

Study Officials

• Tığçe Poyraz İşleyen

  Bahçeşehir University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tuğçe Poyraz İşleyen

CONTACT

+905354467305; tugce.poyrazisleyen@bau.edu.tr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle investigator

Study Record Dates

• First Submitted: July 27, 2026
• First Posted: July 30, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): September 15, 2026
• Study Completion (Estimated): September 15, 2026
• Last Updated: July 31, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)